Abstract
This perspective is the second in a series discussing drugs dropped from development in 2006, with a focus on pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. A survey of discontinued drugs from 2006 is provided, based on data from the Pharmaprojects database, along with an analysis of biology, mechanisms of action and economic considerations in developing new drugs.
MeSH terms
-
Animals
-
Anti-Allergic Agents / adverse effects
-
Anti-Allergic Agents / standards*
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / standards*
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / standards*
-
Drug Approval / methods
-
Drug Industry / methods
-
Drug Industry / standards
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / standards
-
Gastrointestinal Agents / adverse effects
-
Gastrointestinal Agents / standards*
-
Humans
-
Respiratory System Agents / adverse effects
-
Respiratory System Agents / standards*
Substances
-
Anti-Allergic Agents
-
Antirheumatic Agents
-
Dermatologic Agents
-
Drugs, Investigational
-
Gastrointestinal Agents
-
Respiratory System Agents